Drug intelligence / Profile preview

PluroGel

Development stage: Phase 2
Lead developer: Medical Mart
Administration: Topical

Overview

PluroGel is a concentrated surfactant-based wound dressing developed by PluroGen Therapeutics and currently marketed by Medline. It utilizes a proprietary Micelle Matrix technology composed of non-ionic surfactants (poloxamers) that exhibit thermo-reversible properties, allowing the dressing to maintain its viscosity and stay in place at body temperature. PluroGel functions by softening and loosening necrotic tissue, proteinaceous debris, and biofilm through its surfactant action, facilitating non-traumatic debridement and maintaining a moist wound environment. It is indicated for the management of various wound types, including burn injuries, chronic vascular ulcers, and surgical wounds.

Brand names: PluroGel
Other names: Surfactant-based wound dressing

Beyond the preview

Go deeper on PluroGel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PluroGel.

Explore the full profile